Physiological Basis of Bone Remodelling;Remodelage Osseux

Therapie

Volumn 58, Issue 5, 2003, Pages 391-393

  Cohen Solal, Martine ^a   De Vernejoul, Marie Christine ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Bone resorption and formation; Cbfa1; OPG; RANK L

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; WNT PROTEIN;

BONE METASTASIS; BONE REMODELING; CELL DIFFERENTIATION; CELL PROLIFERATION; CONFERENCE PAPER; HORMONAL REGULATION; MECHANICAL STRESS; MYELOMA; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PAGET BONE DISEASE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL;

EID: 0348110415     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2003063     Document Type: Conference Paper

References (12)

1. Ducy P, Zhang R, Geoffroy V, et al. Osf2/Cbfal: a transcriptional activator of osteoblast differentiation. Cell 1997; 89 (5): 747-54
2. Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfal results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997; 89 (5): 755-64
3. Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001 Nov 16; 107 (4): 513-23
4. van de Wetering M, de Lau W, Clevers H. WNT signaling and lymphocyte development. Cell 2002 Apr; 109 Suppl.: S13-9
5. Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002 May 16; 346 (20): 1513-21
6. Kato M, Patel MS, Levasseur R, et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 2002 Apr 15; 157 (2): 303-14
7. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997 Apr 18; 89 (2): 309-19
8. Hofbauer LC, Khosla S, Dunstan CR, et al. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999; 140 (9): 4367-70
9. Giuliani N, Colla S, Sala R, et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 2002 Dec 15; 100 (13): 4615-21
10. Brown JM, Corey E, Lee ZD, et al. Osteoprotegerin and rank ligand expression in prostate cancer. Urology 2001; 57 (4): 611-6
11. Honore P, Luger NM, Sabino MA, et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 2000; 6 (5): 521-8
12. Morony S, Capparelli C, Sarosi I, et al. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001 Jun 1; 61 (11): 4432-6